Objective
"The SYSCID consortium aims to develop a systems medicine approach for disease prediction in CID. We will focus on three major CID indications with distinct characteristics, yet a large overlap of their molecular risk map: inflammatory bowel disease, systemic lupus erythematodes and rheumatoid arthritis. We have joined 15 partners from major cohorts and initiatives in Europe (e.g.IHEC ICGC, TwinsUK and Meta-HIT) to investigate human data sets on three major levels of resolution: whole blood signatures, signatures from purified immune cell types (with a focus on CD14 and CD4/CD8) and selected single cell level analyses. Principle data layers will comprise SNP variome, methylome, transcriptome and gut microbiome. SYSCID employs a dedicated data management infrastructure, strong algorithmic development groups (including an SME for exploitation of innovative software tools for data deconvolution) and will validate results in independent retrospective and prospective clinical cohorts.
Using this setup we will focus on three fundamental aims : (i) the identification of shared and unique ""core disease signatures” which are associated with the disease state and independent of temporal variation, (ii) the generation of ""predictive models of disease outcome""- builds on previous work that pathways/biomarkers for disease outcome are distinct from initial disease risk and may be shared across diseases to guide therapy decisions on an individual patient basis, (iii) ""reprogramming disease""- will identify and target temporally stable epigenetic alterations in macrophages and lymphocytes in epigenome editing approaches as biological validation and potential novel therapeutic tool .
Thus, SYSCID will foster the development of solid biomarkers and models as stratification in future long-term systems medicine clinical trials but also investigate new causative therapies by editing the epigenome code in specific immune cells, e.g. to alleviate macrophage polarization defects."
Fields of science
Not validated
Not validated
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencespersonalized medicine
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
24118 Kiel
Germany
See on map
Participants (16)
WC2R 2LS London
See on map
9052 ZWIJNAARDE - GENT
See on map
CB2 1TN Cambridge
See on map
4000 Liege
See on map
1211 Geneve
See on map
53229 Bonn
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
53113 Bonn
See on map
4365 ESCH-SUR-ALZETTE
See on map
5230 Odense M
See on map
66123 Saarbrucken
See on map
Participation ended
20090 Pieve Emanuele
See on map
115 27 Athina
See on map
31000 OSIJEK
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
10000 Zagreb
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20121 Milano
See on map